A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease

dc.contributor.author	Navas-López, Víctor-Manuel
dc.contributor.author	Pujol-Muncunill, Gemma
dc.contributor.author	Llerena, Enrique
dc.contributor.author	Navalón-Rubio, María
dc.contributor.author	Gil-Ortega, David
dc.contributor.author	Varea-Calderón, Vicente
dc.contributor.author	Sierra-Salinas, Carlos
dc.contributor.author	Martin-de-Carpi, Javier
dc.date.accessioned	2026-02-12T12:02:58Z
dc.date.available	2026-02-12T12:02:58Z
dc.date.issued	2018-02
dc.identifier.citation	Navas-López VM, Pujol Muncunill G, Llerena E, Navalón Rubio M, Gil-Ortega D, Varea-Calderón V, et al. Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn. Anales de Pediatría. febrero de 2018;88(2):89-99.
dc.identifier.issn	1695-4033
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/24163
dc.language.iso	spa
dc.publisher	EDICIONES DOYMA S A
dc.rights	Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.title	A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	28434894
dc.relation.publisherversion	https://linkinghub.elsevier.com/retrieve/pii/S1695403317300528
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.identifier.doi	10.1016/j.anpedi.2017.01.013
dc.journal.title	Anales de Pediatría
dc.identifier.essn	1696-4608